NCT03357887|Completed
Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
T-RIS
Loading search results
T-RIS
Sponsor study identifier
observational
100
1 country
1
Study Start
July 1, 2018
Actual (reported)Primary Completion
December 31, 2018
Actual (reported)Study Completion
December 31, 2018
Actual (reported)To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 14, 2017
Actual (reported)November 30, 2017
Actual (reported)July 1, 2018
Actual (reported)December 31, 2018
Actual (reported)December 31, 2018
Actual (reported)Level of tumour necrosis factor receptor in cerebrospinal fluid
ELISA
Baseline
Level of Neurofilament in cerebrospinal fluid
ELISA
Baseline
Level of GFAP in cerebrospinal fluid
ELISA
Baseline
Level of secreted glycoprotein in cerebrospinal fluid
ELISA
Baseline
Level of tumour necrosis factor receptor in serum
Baseline
Level of Neurofilament in serum
Baseline
Level of GFAP in serum
Baseline
Level of secreted glycoprotein in serum
Baseline
Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients
Baseline
Analysis of biomarkers in patient biological samples
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients from whom prospective samples have been collected and conserved in the biobank at Nice as part of the RISC (Radiologically Isolated Syndrome Consortium). 100 patients with Radiologically Isolated Syndrome as diagnosed by MRI using the Okuda 2009 criteria (65 RIS-: not converted after at least 2 years of follow-up; 35 RIS+). 30 patients with recurrent-remittent multiple sclerosis 30 symptomatic control patients 20 control patients with inflammatory disease 20 control patients with non-inflammatory neurological disease
CHU Nimes
Nîmes, 30029, France
Thouvenot E, Hinsinger G, Demattei C, Uygunoglu U, Castelnovo G, Pittion-Vouyovitch S, Okuda D, Kantarci O, Pelletier D, Lehmann S, Marin P, Siva A, Lebrun C. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Mult Scler. 2019 Apr;25(5):669-677. doi: 10.1177/1352458518767043. Epub 2018 Mar 22.
Blood and cerebrospinal fluid
Eric Thouvenot
CHU Nimes
100 participants (actual enrollment reported by the registry).
First Submitted
November 14, 2017
First Posted
November 30, 2017
Study Start
July 1, 2018
Actual (reported)Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2018
Actual (reported)Study Completion
December 31, 2018
Actual (reported)Last Updated
December 1, 2025
Record last verified: 2020-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: